Comparative efficacy of mycophenolic acid and cyclosporine A in treatment of children with steroid-dependent nephrotic syndrome

   BACKGROUND. Steroid-dependent nephrotic syndrome (SDNS) treatment is still an important problem in pediatric nephrology since the proper use of steroid-sparing agents can reduce the frequency of relapses and avoid steroid toxicity.

   THE AIM of our study was to compare the efficacy of cyclosporine A (CsA) and mycophenolic acid (MPA) in children with SDNS.

   PATIENTS AND METHODS. We observed 91 children (30 girls, 61 boys) with SDNS in 2015-2020. Age at the disease debut was 3 years [2,1; 5,0]. The age at steroid-sparing therapy debut was 8 years [4,0; 16,0]. All children received standard clinical and laboratory examinations and kidney biopsy.

   RESULTS: 25 children were treated with CsA, and 66 children were treated with MPA. The steroid-sparing therapy duration was 36 months [29; 44]. The frequency of relapses before the steroid-sparing therapy onset was 1,32 ± 0,62 (0,5; 4,3)/year, during steroid-sparing therapy it became 0,5 ± 0,58 (0; 2)/year (р < 0,05). Relapse rate in the MPA group was 0,36 ± 0,49 (0; 1,76)/year compared to 0,85 ± 0,66 (0; 2)/year in the CsA group (p < 0,05). Withdrawal of prednisolone was achieved in 44 (48,4 %) children. The relapse-free period during steroid-sparing therapy with steroid withdrawal was 25 months [6; 120]. 15 children (16,5 %) showed long–term stable remission with no immunosuppressive therapy. 14 of them were treated with MPA and only one with CsA (χ²=9,7, р = 0,0021). The remission duration was 7-32,9 months. There were no severe side effects of CsA and MPA requiring discontinuation of therapy.

   CONCLUSION: steroid-sparing therapy of SDNS with CsA and MPA significantly reduces relapse frequency. Relapse risk in patients treated with CsA was significantly higher than with MPA. So, it is justified to prescribe MPA as a first-choice immunosuppressive therapy in patients with SDNS.

1. Avner E., Harmon W., Niaudet P. et al. Idiopathic Nephrotic Syndrome in Children: Clinical Aspects. Pediatric Nephrology, 7th Ed., Berlin, Springer, 2016, p. 839–882

2. Агаронян А. Г. Иммуносупрессивная терапия при стероид-зависимом нефротическом синдроме у детей. Обзор литературы / А. Г. Агаронян [и др.] // Нефрология и диализ. – 2020. – 22 (4): 474–489. doi: 10.28996/2618-9801-2020-4-474-489 / Agaronyan A. G., Vashurina T. V., Komarova O. V. et al. Immunosuppressive therapy in children with steroid dependent nephrotic syndrome. Review. Nephrology and dialysis 2020; 22 (4): 474–489 (In Russ.)

3. Couderc A., Bérard E., Guigonis V. et al. Treatments of steroid-dependent nephrotic syndrome in children. Arch Pediatr 2017 Dec; 24 (12): 1312–1320. doi: 10.1016/j.arcped.2017.09.002

4. Kemper M. J., Valentin L., Van Husen M. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol 2018 Oct; 33 (10): 1641–1649. doi: 10.1007/s00467-017-3780-7

5. Pravitsitthikul N., Willis N., Hodson E. et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome. Cochrane Database Syst Rev 2013 Oct 29 (10): CD002290. doi: 10.1002/14651858.CD002290.pub4

6. Hamasaki Y., Komaki F., Ishikura K. et al. Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment. Accepted: 3 March 2017. Pediatr Nephrol. doi: 10.1007/s00467-017-3641-4

7. Агаронян А. Г. Сравнительная оценка эффективности микофенолата мофетила и циклоспорина А в качестве иммуносупрессивной терапии первой линии у детей со стероид-зависимым нефротическим синдромом / А. Г. Агаронян [и др.] // Нефрология и диализ. – 2020. – 22 (1): 93–98. doi: 10.28996/2618-9801-2020-1-93-98 / Agaronyan A. G., Vashurina T. V., Komarova O. V. et al. Comparative assessment of the efficacy and safety of mycophenolate mofetil versus cyclosporin A in children with steroid dependent nephrotic syndrome. Nephrology and dialysis 2020; 22 (1): 93–98 (In Russ.)

8. Karunamoorthy S., Thanigachalam D., Jeyachandran D. et al. The safety and efficacy of mycophenolate mofetil in children and adolescents with steroid-dependent nephrotic syndrome: a single-centre study. Clinical Kidney Journal 2020; 13 (2): 179–183. doi: 10.1093/ckj/sfz061

9. Nandi M., Mandal S. K., Samanta M. et al. Efficacy of Mycophenolate Mofetil as a Remission Maintaining Agent in Idiopathic Childhood Nephrotic Syndrome. Indian J Nephrol 2019 Jan-Feb; 29 (1): 34–41. doi: 10.4103/ijn.IJN_330_17

10. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney inter Suppl 2012; 2: 139–274

11. Абеуова Б. А. Селективные иммуносупрессоры и алкилирующие агенты в терапии стероидзависимого нефротического синдрома у детей / Б. А. Абеусова [и др.] // Вестник Казахского Национального медицинского университета. – 2013 (1): 14–18 / Abeuova B. A, Naushabayeva A. E., Chingayeva G. N. et al. Selective and alkylating immunosuppressive drugs in therapy of pediatric steroid-dependent nephrotic syndrome. Vestnik Kazahskogo Nacional'nogo medicinskogo universiteta 2013 (1): 14–18 (In Russ.)

12. Afzal K., Bagga A., Menon S. et al. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatr Nephrol 2007 Dec; 22 (12): 2059–2065. doi: 10.1007/s00467-007-0617-9

13. Schwartz G., Muñoz A., Schneider M. et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 Mar; 20 (3): 629–637. doi: 10.1681/ASN.2008030287

14. Jellouli M., Fitouhi S., Abidi K. et al. Mycophenolate mofetil in treatment of childhood steroid-dependent nephrotic syndrome. Tunis Med 2016 Mar; 94 (3): 221–225

15. Dorresteijn E. M., Kist-van Holthe J. E., Levtchenko E. N. et al. Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. Pediatr Nephrol 2008; 23: 2013–2020. doi: 10.1007/s00467-008-0899-6

16. Rahman A., Muinuddin G., Rahman H. et al. Mycophenolate Mofetil versus Cyclosporine in Children with Frequent Relapse Nephrotic Syndrome. J Ped Nephrology 2018; 6 (1). http://journals.sbmu.ac.ir/jpn

17. Gellermann J., Weber L., Pape L. et al. Mycofenolate Mofetil versus Cyclosporin A in children with frequently relapsing nephrotic syndrome. J Am Soc Nephrol 2013; 24 (10): 1689–1697. doi: 10.1681/ASN.2012121200

18. Fujinaga S., Sakuraya K., Yamada А. et al. Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatr Nephrol 2015 (30): 687–691 (2015). doi: 10.1007/s00467-014-3034-x

19. Mendizabal S., Zamona I., Berbel O. et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005; 20 (7): 914–919. doi: 10.1007/s00467-005-1877-x

20. Ogarek I., Szczęsny-horuz E., Wierzchowska-Słowiaczek E. et al. Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children. Pol Merkur Lekarski 2018 Apr 23; 44 (262): 192–195

21. Tellier S., Dallocchio A., Guigonis V. et al. Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid–Dependent Idiopathic Nephrotic Syndrome. Clin J Am Soc Nephrol 2016 Oct 7; 11 (10): 1777–1782. doi: 10.2215/CJN.00320116

22. Dehoux L., Hogan J., Dossier C. et al. Mycophenolate mofetil in steroid-dependent idiopathic nephrotic syndrome. Pediatr Nephrol 2016 Nov; 31 (11): 2095–2101. doi: 10.1007/s00467-016-3400-y

23. Basu B., Babu B. G., Mahapatra T. K. S. Long-term efficacy and safety of common steroid-sparing agents in idiopathic nephrotic children. Clin Exp Nephrol 2017 Feb; 21 (1): 143–151. doi: 10.1007/s10157-016-1266-8

24. Ныркова П. А. Сравнительное исследование эффективности цитостатической терапии первого выбора ингибиторами кальцинейрина и ингибиторами синтеза нуклеотидов гормоночувствительного, гормонозависимого и со стероидной токсичностью нефротического синдрома у детей / П. А. Ныркова, Н. Д. Савенкова // Нефрология. – 2020. – 24 (3): 72–78. https://doi.org/10.36485/1561-6274-2020-24-3-72-78 / Nyrkova P. A., Savenkova N. D. Comparison of first choice cytostatic therapy with calcineurin inhibitors and nucleotides synthesis inhibitors in children with steroid-sensitive, steroid-dependent nephrotic syndrome with steroid toxicity. Nephrology (Saint-Petersburg) 2020; 24 (3): 72–78 (In Russ.)